42% of fund selectors rank China as their top concern compared with 21% globally, according to Natixis Investment Managers’ survey.
The Novo Nordisk share price is up 51% over the past year, while Eli Lilly is up 84%.
After a rough ride during 2021 and 2022, the PGIM Jennison Global Opportunity fund is outperforming in 2023.
Fund managers at Janus Henderson and abrdn share why they are bullish on the healthcare sector.
Dividend kings, JP Morgan’s active drive, Wellington Management’s biopharma video, M&G’s investment mega trends, soaring hedge fund pay, Ray Dalio’s biography, Ottawa madness and much more.
AXA IM identifies two areas within robotech that are likely to weather the recessionary storm.
Short-term sentiment has been boosted after the Chinese government announced plans to relax restrictions, said market observers.
FSA spoke with Julia Angeles, Investment Manager, Baillie Gifford, who discussed why the recent sell-off in the healthcare sector has been excessive, how AI is revolutionising the development of drugs and much more.
Businesses need certain attributes to generate wealth over long periods, not just in short doses, says BNY Mellon Investment Management (BNY Mellon IM).
Energy transition and economic equality are expected to provide investment opportunities for investors in the region.